4.4 Review

Volumetric neuroimaging investigations in mood disorders: bipolar disorder versus major depressive disorder

期刊

BIPOLAR DISORDERS
卷 10, 期 1, 页码 1-37

出版社

WILEY
DOI: 10.1111/j.1399-5618.2008.00435.x

关键词

bipolar disorder; depression; major depressive disorder; mania; MRI; neuroimaging; review

向作者/读者索取更多资源

Background: As patients with mood disorders manifest heterogeneity in phenomenology, pathophysiology, etiology, and treatment response, a biological classification of mental disease is urgently needed to advance research. Patient and methodological variability complicates the comparison of neuroimaging study results and limits heuristic model development and a biologically-based diagnostic schema. Objective: We have critically reviewed and compared the magnetic resonance neuroimaging literature to determine the degree and directionality of volumetric changes in brain regions putatively implicated in the pathophysiology of major depressive disorder (MDD) versus bipolar disorder (BD). Methods: A total of 140 published magnetic resonance imaging investigations evaluating subjects with BD or MDD were selected to provide a summary and interpretation of volumetric neuroimaging results in MDD and BD. Further commentary on the pathophysiological implications, and putative cellular and pharmacological mechanisms, is also provided. Results: While whole brain volumes of patients with mood disorders do not differ from those of healthy controls, regional deficits in the frontal lobe, particularly in the anterior cingulate and the orbitofrontal cortex, appear to consistently differentiate subjects with mood disorders from the general population. Preliminary findings also suggest that subcortical structures, particularly the striatum, amygdala, and hippocampus, may be differentially affected in MDD and BD. Conclusions: Structural neuroimaging studies have consistently identified regional abnormalities in subjects with mood disorders. Future studies should strive to definitively establish the influence of age and medication.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Clinical Neurology

Vortioxetine 20 mg/day in patients with major depressive disorder: updated analysis of efficacy, safety, and optimal timing of dose adjustment

Michael Cronquist Christensen, Roger S. McIntyre, Ioana Florea, Henrik Loft, Andrea Fagiolini

Summary: This study analyzed the efficacy and tolerability of vortioxetine in patients with major depressive disorder. The results showed that vortioxetine 20 mg/day was more effective than 10 mg/day, with similar tolerability. In flexible-dose studies, nearly half of the patients received 20 mg/day after 1 week and two-thirds received 20 mg/day as their final dosage.

CNS SPECTRUMS (2023)

Review Clinical Neurology

Opioid antagonism mitigates antipsychotic-associated weight gain: focus on olanzapine

Roger S. Mcintyre, Leslie Citrome, Hannah Cummings, Mark S. Todtenkopf, Laura A. Tan, Marni White, Sarah Akerman

Summary: The endogenous opioid system plays an important role in weight and metabolism regulation. Targeting this system may help mitigate antipsychotic-induced weight gain and metabolic dysregulation.

CNS SPECTRUMS (2023)

Article Clinical Neurology

Changes in insulin resistance following antidepressant treatment mediate response in major depressive disorder

Houman Rashidian, Mehala Subramaniapillai, Caroline Park, Orly Lipsitz, Hannah Zuckerman, Bing Cao, Yena Lee, Hartej Gill, Roger Nelson Rodrigues, Joshua D. Di Vincenzo, Michelle Iacobucci, Saja Jaberi, Joshua D. Rosenblat, Roger S. McIntyre, Rodrigo B. Mansur

Summary: This study assessed changes in insulin resistance (IR) after antidepressant treatment and found that exacerbation of IR mediated non-response to treatment. In contrast, responders showed a reduction in IR. These findings further elucidate the role of IR in antidepressant response.

JOURNAL OF PSYCHOPHARMACOLOGY (2023)

Article Psychiatry

Exercise effect on the gut microbiota in young adolescents with subthreshold depression: A randomized psychoeducation-controlled Trial

Runhua Wang, Yuanyuan Cai, Weicong Lu, Ruoxi Zhang, Robin Shao, Suk-Yu Yau, Brendon Stubbs, Roger S. McIntyre, Kuan-Pin Su, Guiyun Xu, Liangwen Qi, Kwok-Fai So, Kangguang Lin

Summary: This 3-month randomized psychoeducation-controlled trial examined the effects of exercise on gut microbiota in young adolescents with subthreshold depression. The exercise intervention group showed an increase in the relative abundance of certain genera and species of gut bacteria compared to the psychoeducation-controlled group. These changes were associated with improvements in depressive symptoms and enrichment of defense and signal transduction mechanisms.

PSYCHIATRY RESEARCH (2023)

Review Psychiatry

Oral ketamine for depression: An updated systematic review

Shakila Meshkat, Sipan Haikazian, Joshua D. Di Vincenzo, Farhan Fancy, Danica Johnson, David Chen-Li, Roger S. McIntyre, Rodrigo Mansur, Joshua D. Rosenblat

Summary: This systematic review evaluates the efficacy, tolerability, and safety of oral ketamine, esketamine, and r-ketamine for unipolar and bipolar depression. The results indicate significant antidepressant effects and good tolerability of oral ketamine. However, the included randomized controlled trials had a high risk of bias, and further research with larger sample sizes and longer follow-up periods is needed to determine the antisuicidal effects and efficacy in treatment-resistant depression.

WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY (2023)

Article Clinical Neurology

The efficacy of lumateperone on symptoms of depression in bipolar I and bipolar II disorder: Secondary and post hoc analyses

Roger S. McIntyre, Suresh Durgam, Susan G. Kozauer, Richard Chen, Jason Huo, Robert E. Davis, Andrew J. Cutler

Summary: A recent Phase 3 study showed that lumateperone 42 mg monotherapy effectively improved symptoms of depression in patients with bipolar depression. The study analyzed the change in MADRS scores and found significant improvements in individuals with bipolar I and bipolar II disorder.

EUROPEAN NEUROPSYCHOPHARMACOLOGY (2023)

Review Clinical Neurology

Rethinking ketamine and esketamine action: Are they antidepressants with mood-stabilizing properties?

Giacomo d'Andrea, Mauro Pettorruso, Giorgio Di Lorenzo, Gianluca Mancusi, Roger S. McIntyre, Giovanni Martinotti

Summary: Ketamine and esketamine have generated significant interest as potential therapeutic agents for Treatment-Resistant Depression (TRD). This article provides a comprehensive overview of their action and highlights their effectiveness on mixed features, anxiety, dysphoric mood, and bipolar traits. The complex pharmacodynamic mechanisms of action are discussed, and further research is needed to evaluate the efficacy of esketamine nasal spray in bipolar depression and the potential role of these substances as mood stabilizers.

EUROPEAN NEUROPSYCHOPHARMACOLOGY (2023)

Article Pharmacology & Pharmacy

An update on potential pharmacotherapies for cognitive impairment in bipolar disorder

Danica E. Johnson, Roger S. McIntyre, Rodrigo B. Mansur, Joshua D. Rosenblat

Summary: Cognitive impairment is a significant feature of bipolar disorder, affecting recovery and quality of life. While there are currently no effective treatments for cognitive impairment in bipolar disorder, various pharmacological interventions are being explored as potential options that target the underlying pathophysiology of the disorder.

EXPERT OPINION ON PHARMACOTHERAPY (2023)

Article Clinical Neurology

Associations of stressful life events with subthreshold depressive symptoms and major depressive disorder: The moderating role of gender

Jingman Shi, Xue Han, Yuhua Liao, Hao Zhao, Beifang Fan, Huimin Zhang, Kayla M. Teopiz, Weidong Song, Lingjiang Li, Lan Guo, Ciyong Lu, Roger S. McIntyre

Summary: This study examined the association between stressful life events (SLEs) and subthreshold depressive symptoms (SDS) and major depressive disorder (MDD), with a focus on gender effects. The findings showed that individuals who experienced any SLEs were at a higher risk of SDS and MDD. The association between SLEs and SDS was stronger in females, while the association between SLEs and MDD was stronger in males.

JOURNAL OF AFFECTIVE DISORDERS (2023)

Article Clinical Neurology

Effects of liraglutide on depressive behavior in a mouse depression model and cognition in the probe trial of Morris water maze test

Mi Kyoung Seo, Sehoon Jeong, Dae-Hyun Seog, Jung An Lee, Jae-Hon Lee, Yena Lee, Roger S. McIntyre, Sung Woo Park, Jung Goo Lee

Summary: This study investigated the effects of liraglutide, a GLP-1 agonist, on a depression-like phenotype in mice exposed to chronic unpredictable stress. Liraglutide treatment reduced immobility in the forced swim test and improved cognitive function in the Morris water maze test. These results suggest that GLP-1 agonists could be potential novel antidepressants.

JOURNAL OF AFFECTIVE DISORDERS (2023)

Article Clinical Neurology

Mediating role of personality traits in the association between multi-dimensional adverse childhood experiences and depressive symptoms among older adults: A 9-year prospective cohort study

Yanzhi Li, Lu Cheng, Lan Guo, Liwan Zhu, Hao Zhao, Caiyun Zhang, Manjun Shen, Yifeng Liu, Muhammad Youshay Jawad, Lingjiang Li, Wanxin Wang, Ciyong Lu, Roger S. McIntyre

Summary: This study explores the mediating role of personality traits in the relationship between adverse childhood experiences (ACEs) and depressive symptoms in older adults. The results suggest that maltreatment and household dysfunction induce depressive symptoms by increasing neuroticism, while poor parent-child bonding induces depressive symptoms by increasing neuroticism and reducing conscientiousness and extraversion.

JOURNAL OF AFFECTIVE DISORDERS (2023)

Review Genetics & Heredity

Treatment-Resistant Schizophrenia, Clozapine Resistance, Genetic Associations, and Implications for Precision Psychiatry: A Scoping Review

Jiangbo Ying, Qian Hui Chew, Roger S. McIntyre, Kang Sim

Summary: Treatment-resistant schizophrenia (TRS) is difficult to treat and has a negative impact on patients' quality of life. Clozapine is effective for TRS but has side effects. This review summarizes the current genetic factors associated with TRS, clozapine resistance, and side effects. Further research is needed to identify risk genes and understand the interactions between genes and relevant clinical factors in TRS treatment.
Article Psychiatry

Predictive potential of somatic symptoms for the identification of subthreshold depression and major depressive disorder in primary care settings

Xiuwen Li, Huimin Zhang, Xue Han, Lan Guo, Felicia Ceban, Yuhua Liao, Jingman Shi, Wanxin Wang, Yifeng Liu, Weidong Song, Dongjian Zhu, Hongqiong Wang, Lingjiang Li, Beifang Fan, Ciyong Lu, Roger S. McIntyre

Summary: This study explored the association between somatic symptoms and subthreshold depression (SD) and Major Depressive Disorder (MDD), and determined the predictive potential of somatic symptoms in identifying SD and MDD in primary care. The results showed that somatic symptoms were associated with the presence of SD and MDD, and energy-related symptoms had good predictive potential.

FRONTIERS IN PSYCHIATRY (2023)

Article Biochemistry & Molecular Biology

Combined Administration of Escitalopram Oxalate and Nivolumab Exhibits Synergistic Growth-Inhibitory Effects on Liver Cancer Cells through Inducing Apoptosis

Vincent Chin-Hung Chen, Shao-Lan Huang, Jing-Yu Huang, Tsai-Ching Hsu, Bor-Show Tzang, Roger S. Mcintyre

Summary: The combination of Nivolumab and Escitalopram oxalate was found to have synergistic effects in inhibiting the proliferation of liver cancer cells. This study highlights the potential of combined drug therapy as an alternative treatment option for liver cancer.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Article Oncology

A Phase II, Open-Label Clinical Trial of Intranasal Ketamine for Depression in Patients with Cancer Receiving Palliative Care (INKeD-PC Study)

Joshua D. D. Rosenblat, Froukje E. E. deVries, Zoe Doyle, Roger S. S. McIntyre, Gary Rodin, Camilla Zimmermann, Ernie Mak, Breffni Hannon, Christian Schulz-Quach, Aida Al Kindy, Zeal Patel, Madeline Li

Summary: Ketamine administered through intranasal spray has shown rapid and sustained antidepressant effects in advanced cancer patients suffering from moderate to severe depression. The treatment was well-tolerated with minimal side effects. Further larger-scale controlled trials are needed to confirm these promising findings.

CANCERS (2023)

暂无数据